Hallucinations and sleep disorders in PD: Six-year prospective longitudinal study

Neurology

Volumn 64, Issue 1, 2005, Pages 81-86

  Goetz, Christopher G ^a,c   Wuu, Joanne ^a   Curgian, Linda M ^a,b   Leurgans, Sue ^a  

^a RUSH MEDICAL COLLEGE   (United States)

^b RUSH UNIVERSITY COLLEGE OF NURSING   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; LEVODOPA; NEUROLEPTIC AGENT; SELEGILINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DISEASE COURSE; FEMALE; HALLUCINATION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; NONPARAMETRIC TEST; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SLEEP DISORDER;

EID: 11444270248     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000148479.10865.FE     Document Type: Article

References (18)

1. Goodwin FK. Psychiatric side effects of levodopa in man. JAMA 1971;218:1915-1920.
2. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinsons disease. Neurology 1993;43:2227-2229.
3. Goetz CG, Stebbins GT. Mortality and hallucination in nursing home patients with advanced Parkinson's disease. Neurology 1995;45:669-671.
4. Scaravilli T, Gasparoli E, Rinaldi F. Health-related quality of life and sleep disorders in Parkinson's disease. Neurol Sci 2003;24:209-210.
5. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson's disease. Arch Neurol 1996;53:1265-1258.
6. Celesia GG, Barr AN. Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol 1970;23:193-200.
7. Rye DB. Sleepiness and unintended sleep in Parkinson's disease. Curr Treat Options Neurol 2003;5:231-239.
8. Fahn S, Elton RL, UPDRS program members. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent developments in Parkinsons disease, vol 2. Florham Park, NJ: Macmillan Healthcare Information, 1987;153-163.
9. Goetz CG, Leurgans S, Pappert EJ, Raman R, Sterner AB. Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology 2001;57:2078-2082.
10. Buysse DJ, Reynolds CF, Monk TH, Berman SR. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213.
11. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
12. Zeger SL, Liang K-Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986;42:121-130.
13. SAS Institute Inc. SAS/STAT user's guide, version 8. Cary, NC: SAS Institute Inc., 1999.
14. Lipsitz SR, Kim K, Zhao L. Analysis of repeated categorical data using generalized estimating equations. Stat Med 1994;13:1149-1163.
15. Comella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson's disease in patients with treatment-induced hallucinations. Ann Neurol 1993;34:710-714.
16. Arnulf I, Bonnet AM, Damier P, Bejjani BP. Hallucinations, REM sleep and Parkinson's disease: a medical hypothesis. Neurology 2000;55:281-288.
17. Factor SA, Feustel PJ, Friedman JH, et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 2003;60:1756-1761.
18. Stebbins GT, Goetz CG, Carrillo MC, et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology 2004 (in press).